

To,  
**Bombay Stock Exchange Limited,**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street**  
**Mumbai- 400 001.**

Date: 12.02.2022

**Subject: Outcome of Board Meeting held on 12<sup>th</sup> February, 2022**  
**Ref: Scrip Code: 526546, ISIN: INE493D01013.**

Meeting started at 03.00 P.M. and concluded at 3.45 P.M.

Dear Sir/Madam,

Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, We wish to inform you that following business were transacted at the meeting of the Board of Directors of the Company held on Saturday the day of 12<sup>th</sup> February, 2022 at the registered office of the Company situated at Survey No 9/1, Near Balaji Tulsiyana Industrial Estate, Gram Kumedi, Indore, 452010 MP;

1. The Board has approved and taken on record stand alone Unaudited Financial Results along with Limited review report by the statutory auditors of the Company for the quarter and Nine Month ended on 31<sup>st</sup> December, 2021.

A Copy of results along with Limited review Report of the Statutory Auditors of the Company as required under regulation 33 of the SEBI (LODR) Regulation 2015, is enclosed herewith.

2. The Board has approved the re-appointment of Ms. Himika Choksi as Whole Time Director of the Company, subject to the approval of members in ensuing general meeting w.e.f. 01<sup>st</sup> April, 2022.

Thanking You

Yours faithfully

For **CHOKSI LABORATORIES LIMITED**

For Choksi Laboratories Ltd

  
Company Secretary

**YASH GUPTA**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**


# Subhash Chand Jain Anurag & Associates

Chartered Accountants

104, Archana Apartment, 8-B, Ratlam Kothi, Indore-452001 (MP)

PH # 2519439, 2527682 FAX # 0731 2519116

Email: scjainca2004@yahoo.com



**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**


**Review Report to**

**The Board of Directors**

**Choksi Laboratories Limited**

**Indore (M.P.)-452001**

1. We have reviewed the accompanying statement of unaudited financial results of Choksi Laboratories Limited ("the Company") for the quarter ended December 31, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations").
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) specified under section 133 of the companies act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Subhash Chand Jain Anurag & Associates**  
**Chartered Accounts**  
**FRN: 004733C**



*Akshay Jain*

**(Akshay Jain)**  
**Partner**  
**M.No.447487**

**UDIN: 22447487ABNLKD3688**

**Date: 12/02/2022**  
**Place: Indore**

**CHOKSI LABORATORIES LTD.**

Registered Office : Survey No 9/1, Tulsiana Industrial Park, Kumedi, Indore (MP) 452010

Statement of Unaudited Financial Results for the Quarter and 9 Months Ended on 31st December'2021

|         |  |                           |                           |   |   |  | (Rs. In Lakhs)          |
|---------|--|---------------------------|---------------------------|---|---|--|-------------------------|
| Sl. No. | PARTICULARS  | Quarter Ended             |                           |   | Nine Month Ended                                  |  | Year Ended              |
|         |  | 3 Months ended            | Preceding 3 months ended  | Corresponding 3 months ended in the previous year | Year to Date figures for the current period ended | Year to Date figures for the previous period ended | Previous Year ended     |
|         |  | 31.12.2021<br>(Unaudited) | 30.09.2021<br>(Unaudited) | 31.12.2020<br>(Unaudited)                         | 31.12.2021<br>(Unaudited)                         | 31.12.2020<br>(Unaudited)                          | 31.03.2021<br>(Audited) |
| I       | Revenue from Operation   | 736.96                    | 720.62                    | 616.70  | 1990.42   | 1834.32  | 2568.80                 |
| II      | Other Income   | 0.36                      | 0.23                      | 21.12   | 9.79  | 46.25  | 48.82                   |
| III     | <b>Total Income (I+II)</b>   | <b>737.32</b>             | <b>720.85</b>             | <b>637.82</b>                                     | <b>2000.21</b>                                    | <b>1880.57</b>                                     | <b>2617.62</b>          |
| IV      | <b>Expenses</b>  |                           |                           |   |   |  |                         |
|         | (a) Cost of materials consumed   | 48.67                     | 53.52                     | 55.36   | 153.19  | 191.70   | 256.53                  |
|         | (b) Employee benefits expenses   | 297.38                    | 315.84                    | 290.08  | 886.28  | 833.74   | 1150.08                 |
|         | (c) Finance Cost   | 75.61                     | 82.81                     | 68.37   | 244.91  | 197.06   | 281.83                  |
|         | (d) Depreciation and amortisation expense  | 135.97                    | 136.50                    | 113.77  | 408.15  | 334.63   | 460.30                  |
|         | (e) Laboratories Maintenance Expenses  | 57.69                     | 68.75                     | 84.24   | 179.86  | 197.70   | 264.53                  |
|         | (f) Power & Fuel Charges   | 17.42                     | 19.09                     | 18.19   | 54.07   | 53.60  | 65.69                   |
|         | (g) Other expenses   | 100.68                    | 89.21                     | 107.53  | 298.22  | 310.15   | 419.48                  |
|         | <b>Total expenses</b>  | <b>733.42</b>             | <b>765.72</b>             | <b>737.54</b>                                     | <b>2224.68</b>                                    | <b>2118.58</b>                                     | <b>2898.44</b>          |
| V       | <b>Profit/(Loss) before exceptional items and tax (III-IV)</b>                   | <b>3.90</b>               | <b>(44.87)</b>            | <b>(99.72)</b>                                    | <b>(224.47)</b>                                   | <b>(238.01)</b>                                    | <b>(280.82)</b>         |
| VI      | Exceptional items  | -                         | -                         | -   | -   | -  | -                       |
| VII     | <b>Profit/(Loss) before tax (V-VI)</b>   | <b>3.90</b>               | <b>(44.87)</b>            | <b>(99.72)</b>                                    | <b>(224.47)</b>                                   | <b>(238.01)</b>                                    | <b>(280.82)</b>         |
| VIII    | <b>Tax Expenses</b>  |                           |                           |   |   |  |                         |
|         | (a) Current Tax  | 0.00                      | 0.00                      | 0.00  | 0.00  | 0.00   | 0.00                    |
|         | (b) Deferred Tax   | 1.04                      | 7.63                      | 8.11  | (21.27)   | (16.24)  | (20.05)                 |
| IX      | <b>Profit/(Loss) for the period (VII-VIII)</b>                                   | <b>2.86</b>               | <b>(52.50)</b>            | <b>(107.83)</b>                                   | <b>(203.20)</b>                                   | <b>(221.77)</b>                                    | <b>(260.77)</b>         |
| X       | <b>Other Comprehensive Income</b>  |                           |                           |   |   |  |                         |
|         | (a) (i) Items that will not be reclassified to profit & loss                     | 4.50                      | 4.50                      | 2.50  | 13.50   | 7.50   | 18.04                   |
|         | (ii) Income tax relating to items that will not be reclassified to profit & loss | (1.17)                    | (1.17)                    | (0.65)  | (3.51)  | (1.95)   | (4.69)                  |
|         | (b) (i) Items that will be re-classified to profit & loss                        | -                         | -                         | -   | -   | -  | -                       |
|         | (ii) Income tax relating to items that will be reclassified to profit & loss     | -                         | -                         | -   | -   | -  | -                       |
| XI      | <b>Total Comprehensive Income (IX+X)</b>   | <b>6.19</b>               | <b>(49.17)</b>            | <b>(105.98)</b>                                   | <b>(193.21)</b>                                   | <b>(216.22)</b>                                    | <b>(247.42)</b>         |
| XII     | <b>Details of Equity Share Capital</b>   |                           |                           |   |   |  |                         |
|         | (a) Paid-up equity share capital   | 696.52                    | 696.52                    | 696.52  | 696.52  | 696.52   | 696.52                  |
|         | (b) Face value of equity share capital   | 10.00                     | 10.00                     | 10.00   | 10.00   | 10.00  | 10.00                   |
| XIII    | <b>Earnings per equity share (for continuing operation)</b>                      |                           |                           |   |   |  |                         |
|         | (a) Basic  | 0.04                      | (0.75)                    | (1.55)  | (2.92)  | (3.18)   | (3.74)                  |
|         | (b) Diluted  | 0.04                      | (0.75)                    | (1.55)  | (2.92)  | (3.18)   | (3.74)                  |
| XIV     | <b>Earnings per equity share (for discontinued operation)</b>                    |                           |                           |   |   |  |                         |
|         | (a) Basic  | -                         | -                         | -   | -   | -  | -                       |
|         | (b) Diluted  | -                         | -                         | -   | -   | -  | -                       |
| XV      | <b>Earnings per equity share (for discontinued and continuing operation)</b>     |                           |                           |   |   |  |                         |
|         | (a) Basic  | 0.04                      | (0.75)                    | (1.55)  | (2.92)  | (3.18)   | (3.74)                  |
|         | (b) Diluted  | 0.04                      | (0.75)                    | (1.55)  | (2.92)  | (3.18)   | (3.74)                  |

Cont.



Note

Page - 2

- 1 These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.
- 2 "Other Income" for the quarter and Nine month ended on 31 December 2021 includes :-  
Interest Income at fair value as per IND AS Rs. 29,175/-, Interest on Deposits Rs. 2,71,413/-, Interest on IT refund Rs. 6,41,718/-, Profit on Foreign Exchange Rs. 6,035/- & Profit on Sales of Fixed Assets Rs. 30,234/-
- 3 The Company continues to consider the impact of COVID-19 pandemic in assessing the recoverability of receivables, and intangible assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions including sensitivity analysis expects to fully recover the carrying amount of receivables, intangible assets, and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
- 4 The figures for the quarter and nine month ended on 31st December, 2021 are the balancing figures between unaudited figures in respect of the nine month ended on December 31, 2021 and the published unaudited figures for the half year ended on September 30, 2021
- 5 The above Financial Results for the quarter and nine month ended on 31st December 2021 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Wednesday, 12th February 2022.
- 6 The results for the quarter and nine month ended on 31st December 2021 are subject to "Limited Review" by the Statutory Auditors and their report contains no qualification.
- 7 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful life of assets.
- 8 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".
- 9 Revenue from Operations is recorded exclusive of GST
- 10 Earnings per share amount shown in Rupees.
- 11 Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's Companies Act, 2013 effective 1st April 2021.
- 12 For any queries e\_mail at compliance\_officer@choksilab.com

Place : Indore  
Date : 12.02.2022

By Order of the Board  
For Choksi Laboratories Limited

  
Sunil Choksi  
Managing Director  
DIN : 00155076

